Paradigm Health Acquires Flatiron’s Clinical Research Business for $78M

Paradigm Health has announced its acquisition of Flatiron Health’s Clinical Research Business for $78 million, a move that significantly alters the landscape of oncology trials in the United States. This transaction also establishes a long-term strategic partnership aimed at enhancing the accessibility and efficiency of clinical research for patients nationwide.

The acquisition merges Paradigm Health’s expansive technology-driven oncology research network with Flatiron’s advanced artificial intelligence (AI) trial infrastructure. Together, they aim to create a cohesive ecosystem that broadens trial capacity, minimizes operational challenges, and delivers more representative evidence for oncology treatments.

Transforming Oncology Trials Across the U.S.

With this acquisition, Paradigm Health’s network now encompasses over 25 academic medical centers and health systems, nearly 100 community oncology practices, and serves more than 2.4 million patients across the country. The integration of Flatiron Health’s established research tools, particularly its OncoEMR network, is designed to enhance the clinical trial experience by embedding research into the existing care settings where patients already receive treatment. This is especially vital for rural and underserved populations, who often face barriers in accessing clinical trials.

The unified platform will allow sponsors and sites to function within a single AI-enabled workflow. This streamlining of processes is expected to accelerate documentation, improve feasibility assessments, and reduce the infrastructure burden typically placed on clinical sites. Both organizations have emphasized that the partnership will facilitate a seamless transition for health systems and community clinics, preserving existing research relationships while incorporating advanced digital capabilities.

Impact on Biopharma Sponsors and Evidence Generation

The collaboration strengthens Paradigm’s capacity to assist biopharmaceutical sponsors comprehensively. This includes the ability to conduct pragmatic Phase IV studies within real-world care settings, which is crucial for generating relevant post-market evidence. By harnessing the complementary strengths of both companies, the partnership aspires to rebuild the U.S. clinical research ecosystem, making it more inclusive and aligned with national priorities for modernizing trial delivery.

The overarching objective is clear: create a research infrastructure that mirrors real-world populations, diminishes barriers for healthcare providers, and expands access to clinical trials within community settings. This initiative ultimately aims to expedite the introduction of new therapies to patients, enhancing the overall effectiveness of oncology treatment across the country.

While the terms of the transaction remain undisclosed, the strategic implications for both Paradigm Health and Flatiron Health are significant. This acquisition not only represents a financial investment but also a commitment to reshaping how clinical research is conducted, ensuring that it is more accessible and effective for all patients.